Rare Cancer Series | VHL-Associated Cancers

In our exclusive interview, Dr. Nichols discusses von Hippel-Lindau disease in great detail, how she currently approaches treatment with these patients, and the importance of routine surveillance in this population.

Kim E. Nichols, MD, discusses the prognosis of patients with von Hippel-Lindau disease.

Those diagnosed with von Hippel-Lindau disease have a resource for that complete and coordinated care in Roswell Park Comprehensive Cancer Center, which was recently named a VHL Clinical Care Center by the VHL Alliance.

VHL disease is defined as a rare, inherited disorder that causes tumors and cysts to grow in specific areas of the body, including the brain, spinal cord, eyes, inner ear, adrenal glands, pancreas, kidney, and reproductive tract.

Recent research for effective therapies designed to target von Hippel-Lindau disease–associated renal cell carcinoma is pointing to a future with the paradigm that comprises immunotherapy, HIF-2α inhibitors, and potentially CDK4/6 inhibitors.